ANDA 209509, held by PH Health. Ambrisentan.
As of Nov 21, 2026, ANDA 209509 (Ambrisentan), held by PH Health, was first approved by FDA on Apr 10, 2019, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 10, 2019 | Original application | Approved |
| Ambrisentan5MG ยท tablet;oral | Ambrisentan | Discontinued |
| Ambrisentan10MG ยท tablet;oral | Ambrisentan | Discontinued |
| Apr 4, 2025 | Supplement 6REMS | Approved | None posted |
| Aug 19, 2024 | Supplement 5REMS | Approved | None posted |
| Jun 8, 2021 | Supplement 4REMS | Approved | None posted |
| Dec 22, 2020 | Supplement 2REMS | Approved | None posted |
| Nov 29, 2019 | Supplement 1Labeling ยท Standard review | Approved | None posted |
| Apr 10, 2019 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters